Previous 10 | Next 10 |
Investing in penny stocks is often regarded as an effective way for new investors to make money in the market. It’s also a way to leverage small amounts of capital to make large windfalls. I won’t bore you with the details of how to make money with penny stocks. Honestly, it ...
VANCOUVER, Washington, Feb. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, anno...
CytoDyn ( OTCQB:CYDY ) is a classic boom bust stock. Its fanboys are convinced that its leronlimab will become the next powerhouse HIV therapy, not to mention cancer, NASH etc. Others such as myself, on most days not so much, per earlier articles here and here . I feel that CytoDyn has ...
VANCOUVER, Washington, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...
Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...
VANCOUVER, Washington, Feb. 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced t...
CytoDyn ( OTCQB:CYDY ) holders have filed to offer up to 16.03M shares, including shares underlying warrants and preferred stock. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
CytoDyn ( OTCQB:CYDY ) reports strong data from patients in its clinical trials with metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). More news on: CytoDyn Inc., Healthcare stocks news, Stocks on the move, Read more ...
VANCOUVER, Washington, Jan. 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
The Big Game Is This Weekend; Looking or Some Penny Stocks To Watch? The biggest game in football will be hosted in Miami, FL this weekend but what does that mean for penny stocks ? Well, honestly, not much but when people are spending thousands on football tickets, they’re likely look...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...